Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 55Myelodysplastic Syndromes 19Recurrence 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia, Myelomonocytic, Chronic 12Lymphoma, Non-Hodgkin 11Leukemia 11Multiple Myeloma 9Lymphoma, Mantle-Cell 7Hematologic Neoplasms 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Follicular 6Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myeloid 3Burkitt Lymphoma 3Neoplasms 2Neoplasm, Residual 2Myeloproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Biphenotypic, Acute 2Immunoglobulin Light-chain Amyloidosis 2Dendritic Cell Sarcoma, Interdigitating 2Waldenstrom Macroglobulinemia 1Thrombocytosis 1Thrombocythemia, Essential 1

Interventions

ibrutinib 2Rituximab 2venetoclax 1ponatinib 1fludarabine 1enzalutamide 1durvalumab 1dacetuzumab 1blinatumomab 1Lenalidomide 1Cyclophosphamide 1CA-4948 1Bendamustine Hydrochloride 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphatic Diseases × venetoclax × Clear all
NCT02265731 2021-08-02

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

AbbVie

Phase 1/2 Completed
38 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡